Nuala Moran

The UK may have used its veto on treaty change, but it will support increased spending on R&D from 2014 – 2020, as proposed in Horizon 2020. Cutting agriculture subsidies could pay for this, Business Minister Vince Cable tells Science|Business

The promise of accelerated approvals and higher pricing has persuaded pharmaceutical companies to break the deadlock in antibiotic R&D

Entrepreneurship is the route to growth and job creation. But don’t try and kid Europe’s unemployed youth they can all be entrepreneurs.

There’s plenty of (empirical) evidence to justify specific measures to put women scientists on an equal footing with their male counterparts. A Gender Summit next week must make an unambiguous call for Horizon 2020 to embrace this view

The ruling will hit investment by industry in the development of cell therapies and means European research will be commercialised elsewhere

Sixteen of Europe’s top medical research bodies state their case for urgent reform of clinical trials regulations as they begin to prepare the ground for the parliamentary debate on rule changes, expected next year

Uppsala BIO cluster is to become the ninth member of the Swiss pharma’s global network for early-stage research

A new treatment for prostate cancer launched in the UK this week. The drug was discovered by scientists in London, funded by the public. So why is it owned by a US pharma giant?

Deals take a notoriously long time to close in biotech. Maybe that’s why so many came to fruition in August

With plans for a new UK research and innovation strategy on the drawing board, the influential charity, Cancer Research UK, is leading a call for the government to build an “ideal environment” for research.